Evidence map›Paper›PMID 32616529›Full record

ArticleHaematologica2021

CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity.

Julia C Gutjahr, Elisabeth Bayer, Xiaobing Yu, Julia M Laufer, Jan P Höpner, Suzana Tesanovic, Andrea Härzschel, Georg Auer, Tanja Rieß, Astrid Salmhofer and 15 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia.International journal of molecular sciences · 2024
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. The biology of E-selectin ligands in leukemogenesis.Advances in cancer research · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 4 countries.

Julia C Gutjahr3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg.
Elisabeth Bayer3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg.
Xiaobing YuKarlsruhe Institute of Technology, Institute of Toxicology and Genetics.
Julia M LauferBiotechnology Institute Thurgau (BITg) at the University of Konstanz.
Jan P Höpner3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg.
Suzana TesanovicDepartment Biosciences, Paris-Lodron University of Salzburg.
Andrea HärzschelDepartment of Internal Medicine I, Medical Center and Faculty of Medicine, University of Freiburg.
Georg Auer3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg.
Tanja Rieß3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg.
Astrid Salmhofer3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg.
Eva Szenes3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg.
Theresa Haslauer3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg.
Valerie Durand-Onayli3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg.
Andrea RamspacherDepartment Biosciences, Paris-Lodron University of Salzburg.
Sandra P PennisiDepartment of Internal Medicine I, Medical Center and Faculty of Medicine, University of Freiburg.
Marc ArtingerBiotechnology Institute Thurgau (BITg) at the University of Konstanz, Kreuzlingen, Switzerland.
Nadja Zaborsky1Laboratory for Immunological and Molecular Cancer Research.
Alexandre ChigaevDepartment of Pathology and Cancer Center, University of New Mexico.
Fritz AbergerDepartment Biosciences, Paris-Lodron University of Salzburg.
Daniel NeureiterInstitute of Pathology, Paracelsus Medical University Salzburg.
Lisa Pleyer3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg.
Daniel F LeglerBiotechnology Institute Thurgau (BITg) at the University of Konstanz.
Veronique Orian-RousseauKarlsruhe Institute of Technology, Institute of Toxicology and Genetics.
Richard Greil3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg.
Tanja N Hartmann3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg.
Paracelsus Medical University · ATUniversity of Salzburg · ATBiotechnology Institute Thurgau · CHKarlsruhe Institute of Technology · DENew Mexico Cancer Center · USUniversity Medical Center Freiburg · DEUniversity of Freiburg · DEUniversity of Konstanz · DE

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
NCI NIH HHS P30 CA118100
6 · The paper itself

Abstract

Adhesive properties of leukemia cells shape the degree of organ infiltration and the extent of leukocytosis. CD44 and the integrin VLA-4, a CD49d/CD29 heterodimer, are important factors of progenitor cell adhesion in bone marrow (BM). Here, we report their cooperation in acute myeloid leukemia (AML) by a novel non-classical CD44-mediated way of inside-out VLA-4 activation. In primary AML BM samples from patients and the OCI-AML3 cell line, CD44 engagement by hyaluronan induced inside-out activation of VLA-4 resulting in enhanced leukemia cell adhesion on VCAM-1. This was independent from VLA-4 affinity regulation but based on ligand-induced integrin clustering on the cell surface. CD44-induced VLA-4 activation could be inhibited by the Src family kinase inhibitor PP2 and the multikinase inhibitor midostaurin. In further consequence, the increased adhesion on VCAM-1 allowed AML cells to strongly bind stromal cells. Thereby VLA-4/VCAM-1 interaction promoted activation of Akt, MAPK, NF-kB and mTOR signaling and decreased AML cell apoptosis. Collectively, our investigations provide a mechanistic description of an unusual CD44 function in regulating VLA-4 avidity in AML, supporting AML cell retention in the supportive BM microenvironment.

Indexed as

Integrin alpha4beta1Leukemia, Myeloid, AcuteBone MarrowCell AdhesionHumansHyaluronan ReceptorsTumor MicroenvironmentVascular Cell Adhesion Molecule-1CD44 protein, humanHyaluronan ReceptorsIntegrin alpha4beta1Vascular Cell Adhesion Molecule-1

Identifiers

PMID32616529
PMCPMC8327716
OpenAlexW3039157487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.